Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Habitual coffee consumption and blood pressure: An epidemiological perspective

Authors Johanna M Geleijnse

Published Date August 2008 Volume 2008:4(5) Pages 963—970


Published 5 August 2008

Johanna M Geleijnse

Division of Human Nutrition, Wageningen University, The Netherlands

Abstract: This paper summarizes the current epidemiological evidence on coffee consumption in relation to blood pressure (BP) and risk of hypertension. Data from crosssectional studies suggest an inverse linear or U-shaped association of habitual coffee use with BP in different populations. Prospective studies suggest a protective effect of high coffee intake (4 or more cups per day) against hypertension, mainly in women. Furthermore, the risk of hypertension may be lower in coffee abstainers. Randomized controlled trials, which are mostly of short duration (1–12 weeks), have shown that coffee intake around 5 cups per day causes a small elevation in BP (∼2/1 mmHg) when compared to abstinence or use of decaffeinated coffee. With regard to underlying biological mechanisms, most research has been devoted to BP-raising effects of caffeine. However, there are many other substances in coffee, such as polyphenols, soluble fi bre and potassium, which could exert a beneficial effect in the cardiovascular system. Although the precise nature of the relation between coffee and BP is still unclear, most evidence suggests that regular intake of caffeinated coffee does not increase the risk of hypertension.

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy

Estevanato LC, Da Silva JR, Falqueiro AM, Mosiniewicz-Szablewska E, Suchocki P, Tedesco AC, Morais PC, Lacava ZG

International Journal of Nanomedicine 2012, 7:5287-5299

Published Date: 5 October 2012

Progress on RNAi-based molecular medicines

Chen J, Xie JP

International Journal of Nanomedicine 2012, 7:3971-3980

Published Date: 26 July 2012

Update on pediatric dystonias: etiology, epidemiology, and management

Fernández-Alvarez E, Nardocci N

Degenerative Neurological and Neuromuscular Disease 2012, 2:29-41

Published Date: 12 April 2012

Effect of gene environment interactions on lung function and cardiovascular disease in COPD

Hackett TL, Stefanowicz D, Aminuddin F, Sin DD, Connett JE, Anthonisen NR, Paré PD, Sandford AJ

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:277-287

Published Date: 10 May 2011

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy

SA Kingsberg, S Kellogg, M Krychman

International Journal of Women's Health 2009, 1:105-111

Published Date: 20 August 2009

The characteristics of keratomycosis by Beauveria bassiana and its successful treatment with antimycotic agents

Hiroko Sonoyama, Kaoru Araki-Sasaki, Shigeyasu Kazama, Tsutomu Kawasaki, Hidenao Ideta, et al

Clinical Ophthalmology 2008, 2:675-678

Published Date: 9 October 2008

Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: focus on insulin glulisine

Heather Ulrich, Benjamin Snyder, Satish K Garg

Vascular Health and Risk Management 2007, 3:245-254

Published Date: 15 August 2007

Studies on free radicals, antioxidants, and co-factors

Khalid Rahman

Clinical Interventions in Aging 2007, 2:219-236

Published Date: 14 August 2007